Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term metastatic. Found 15 abstracts

Kaplon AW, Galloway TJ, Bhayani MK, Liu JC. Effect of HPV Status on Survival of Oropharynx Cancer with Distant Metastasis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020 Mar 24;:194599820913604.
Hammel P, Kindler HL, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 Dec;30(12):1959-68.   PMCID: PMC6938600
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Colt DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):366-400.   PMCID: not NIH funded
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. Occult Primary Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2011 Dec;9(12):1358-95.   PMCID: not NIH funded
Kim S, Eleff M, Nicolaou N. CETUXIMAB AS PRIMARY TREATMENT FOR CUTANEOUS SQUAMOUS CELL CARCINOMA TO THE NECK. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Feb;33(2):286-8.   PMCID: *
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G(1) Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology. 2010 Feb;28(5):780-7.   PMCID: PMC2834394
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen L, Meropol NJ. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology. 2009 Jul;20(7):1223-9.   PMCID: Private funding
Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK. Melanoma. Journal of the National Comprehensive Cancer Network. 2009 Mar;7(3):250-75.   PMCID: not NIH funded
Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics. 2009 Nov;9(8):777-85.   PMCID: PMC2810399
Epstein BE, Pajak TF, Haulk TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma - Prognostic features and natural history. American Journal of Clinical Oncology-Cancer Clinical Trials. 1999 Feb;22(1):22-8.
Hanks GE, Peters T, Owen J. Seminoma of the Testis - Long-Term Beneficial and Deleterious Results of Radiation. International Journal of Radiation Oncology Biology Physics. 1992 Jan;24(5):913-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term metastatic

metastatic chemotherapy cancer antitumor-activity positron-emission-tomography colorectal-cancer renal-cell carcinoma skin malignant-melanoma BEVACIZUMAB NCCN Guidelines cooperative-oncology-group NCCN Clinical Practice Guidelines colorectal cancer primary cutaneous melanoma renal cell carcinoma lymph-node biopsy randomized high-risk melanoma IRINOTECAN erlotinib biopsy FLUOROURACIL transitional-cell carcinoma guanylyl cyclase c health-related quality of life squamous cell carcinoma surgical excision multikinase 2nd-line treatment therapy squamous-cell carcinoma angiogenesis occult primary cetuximab Brca adjuvant breast phase 2 surgical gemcitabine patterns of 2009 doloff da-j natl compr canc s2-v7-p1 interferon phase-iii sentinel lymph node oropharyngeal carcinoma mediastinal irradiation vascular endothelial growth factor chain-reaction assay growth-factor receptor gefitinib poorly growth-factor-receptor cardiac injury phase-ii raf kinase 7 days 2nd cancers adjuvant therapy PLUS LEUCOVORIN contrast-enhanced mri ramucirumab surrogate end-points high-dose interferon-alpha-2b unknown primary site antiferritin lymph node dissection diastolic blood-pressure AG-013736 cutaneous prognostic-factors early-stage melanoma transcriptase PCR american joint committee cyclic-gmp bladder-cancer hodgkins-disease human papillomavirus predictive marker therapy-oncology-group differentiated adenocarcinoma care testicular seminoma plus cetuximab expression margin TRIAL dose-escalation bevacizumab CHEMOTHERAPY Pancreatic cancer drug development VEGF solid tumors monoclonal staging ii colon-cancer recombinant interleukin-2 therapy disease circulating tumor cells curative resection malignant-tumors experience PROGNOSTIC-FACTORS refractory solid tumors hepatoma fibrolamellar escherichia-coli carcinoma of unknown primary antibody SELECTION Oncology 1993 n jkl-journal of dermatologic surgery and oncology-v19-p985 tumor plus irinotecan primary tumors seminoma patterns metastases SCC endothelial growth-factor CANCER TUMORS radiation therapy GROWTH gastrointestinal stromal tumors head and neck cancer controlled-trials cancer-research-network olaparib angiogenesis inhibitor SUNITINIB phase-ii trial tyrosine kinase liver pathology inhibitor isolated limb perfusion days on lymph node sunitinib quantitative reverse stage-iii melanoma GUCY2C SORAFENIB pharmacokinetics OXALIPLATIN metastatic carcinoma melanoma
Last updated on Monday, July 06, 2020